查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026051

不可切除肝細胞癌（uHCC）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Unresectable Hepatocellular Carcinoma (uHCC) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 155 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 英國uHCC 市場預計將從 2025 年的 4,900 萬美元成長到 2035 年的 7,100 萬美元，顯示市場穩步擴張。
  • 市場成長受以下因素驅動：
  • 擴大昂貴聯合治療的使用
  • 透過改進診斷技術，擴大可治療的患者範圍。
  • 儘管流行病學成長是漸進的，但生物製藥的高成本和較長的治療週期支撐了市場規模。
  • 歐洲強而有力的健保報銷機制持續促進人們獲得創新治療方法。
  • 未來的成長取決於下一代免疫療法和針對抗藥性機制的新型聯合治療策略。

不可切除肝細胞癌（uHCC）：概述

不可切除的肝細胞癌 (uHCC) 是一種晚期、高度原發性的原發性肝癌，其特徵是肝內腫瘤負荷廣泛、多發性病灶、侵犯主要血管或肝功能障礙，使得手術切除或肝移植等根治性干預措施成為不可能。

這種疾病主要發生於慢性肝損傷或肝硬化的基礎上，其原因包括B型和C型肝炎、酒精性肝病以及代謝功能障礙相關性脂肪肝（MASLD）。從生物學角度來看，uHCC 的特徵是顯著的血管生成、免疫逃脫以及致癌性訊號通路的活化。

臨床上，此病常表現為進行進行性肝衰竭，包括難治性腹水、黃疸和門靜脈高壓，導致預後不良。晚期，細胞毒性化學療法的療效有限，局部和區域治療的可行性較低；因此，治療主要集中於全身性治療。

治療模式已發生顯著變化，第一線治療方案已轉向聯合治療，特別是免疫查核點阻斷劑（PD-1/PD-L1阻斷劑）與抗血管新生藥物（VEGF阻斷劑）或CTLA-4阻斷劑的聯合應用。這已證實可提高存活率，並正在重新定義標準治療方案。

主要亮點

  • 在法國，預計新增病例數將從 2025 年的 7,874 例增加到 2035 年的 8,033 例，這表明疾病負擔略有增加。
  • 診斷率仍高達 85.0%，反映出整個醫療保健系統具有很高的偵測能力。
  • 治療率仍只有 76.2%，凸顯了確診患者與接受治療的患者之間仍然存在的差距。
  • 治療模式正朝向以免疫療法為基礎的聯合治療（IO + 抗 VEGF/CTLA-4）轉變，成為新的治療標準。
  • 儘管近年來治療方法取得了進展，但晚期患者或對治療有抗藥性的患者仍然存在未被滿足的需求。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • InnoBM Pharmaceuticals Co., Ltd.
  • Chengdu New Radiomedicine Technology Co. LTD.
  • BeiGene
  • Hoffmann-La Roche
  • Beijing Gene Key Life Technology Co., Ltd
  • Akeso
  • AstraZeneca
  • Tvardi Therapeutics, Incorporated
  • Genentech, Inc.
  • RayzeBio, Inc.
  • Shanghai Henlius Biotech

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興治療方法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Unresectable Hepatocellular Carcinoma (uHCC) Market Outlook

Thelansis's "Unresectable Hepatocellular Carcinoma (uHCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Unresectable Hepatocellular Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Unresectable Hepatocellular Carcinoma (uHCC): Overview

Unresectable hepatocellular carcinoma (uHCC) represents an advanced, highly aggressive form of primary liver cancer characterized by extensive intrahepatic tumor burden, multifocal disease, macrovascular invasion, or compromised hepatic function that precludes curative interventions such as surgical resection or liver transplantation.

The disease arises predominantly in the setting of chronic liver injury and cirrhosis, driven by etiologies including hepatitis B and C infections, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease (MASLD). Biologically, uHCC is marked by pronounced angiogenesis, immune evasion, and activation of oncogenic signaling pathways.

Clinically, patients often present with progressive hepatic decompensation, including refractory ascites, jaundice, and portal hypertension, contributing to poor prognosis. Given the limited efficacy of cytotoxic chemotherapy and reduced feasibility of locoregional therapies in advanced stages, treatment is primarily systemic.

The therapeutic paradigm has evolved significantly, with frontline treatment shifting toward combination regimens-particularly immune checkpoint inhibitors (PD-1/PD-L1 inhibitors) combined with anti-angiogenic agents (VEGF inhibitors) or CTLA-4 blockade-demonstrating improved survival outcomes and redefining the standard of care.

Key Highlights

  • In France, incident cases are projected to increase from 7,874 in 2025 to 8,033 by 2035, indicating marginal growth in disease burden.
  • Diagnosis rate remains high at 85.0%, reflecting strong detection capabilities across healthcare systems.
  • Treatment rate stands at 76.2%, highlighting a residual gap between diagnosed and treated patients.
  • The treatment paradigm has shifted toward immunotherapy-based combinations (IO + anti-VEGF/CTLA-4) as the new standard of care.
  • Persistent unmet need exists in post-progression settings and treatment-resistant populations, despite recent therapeutic advances.

Market Overview

  • The United Kingdom uHCC market is projected to grow from $49M in 2025 to $71M by 2035, reflecting steady market expansion.
  • Market growth is driven by:
  • Increasing adoption of high-cost immunotherapy combinations
  • Expansion of eligible patient population due to improved diagnosis
  • Despite modest epidemiological growth, market value is supported by premium-priced biologics and longer treatment duration.
  • Strong reimbursement frameworks in Europe continue to facilitate access to innovative therapies.
  • Future growth will depend on next-generation immunotherapies and novel combination strategies targeting resistance mechanisms.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • InnoBM Pharmaceuticals Co., Ltd.
  • Chengdu New Radiomedicine Technology Co. LTD.
  • BeiGene
  • Hoffmann-La Roche
  • Beijing Gene Key Life Technology Co., Ltd
  • Akeso
  • AstraZeneca
  • Tvardi Therapeutics, Incorporated
  • Genentech, Inc.
  • RayzeBio, Inc.
  • Shanghai Henlius Biotech

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)